论文部分内容阅读
用１５３Ｓｍ－ＥＤＴＭＰ治疗１６７例恶性骨肿瘤及骨转移癌，观察血象及骨髓象的变化。采用每公斤体重０．８ｍＣｉ及１．０ｍＣｉ计算治疗总计量。治疗后骨痛改善者１５６例（９３．４１％）。不同治疗剂量对止痛疗效、血象和骨髓象未见明显差异（Ｐ＞０．１）。治疗后红细胞、血小板和白细胞总数及其中性、淋巴细胞均较治疗前下降（Ｐ＜０．０１），９例病人在１５３Ｓｍ治疗期间同时应用化疗及局部放疗，发现全血象降低，骨髓抑制，其中４例为轻度再生障碍性贫血。因此，在应用放疗及化疗期间应慎重使用１５３Ｓｍ，并严密监视血象及骨髓变化
167 cases of malignant bone tumors and bone metastases were treated with 153Sm-EDTMP, and the changes of blood and bone marrow were observed. The total treatment volume was calculated using 0.8 mCi and 1.0 mCi per kilogram of body weight. 156 cases improved after treatment of bone pain (93.41%). Different therapeutic doses of analgesic efficacy, blood and bone marrow showed no significant difference (P> 0.1). After treatment, the total number of erythrocytes, platelets and white blood cells, their neutrality and lymphocytes decreased compared with those before treatment (P <0.01). Nine patients underwent both chemotherapy and local radiotherapy during 153Sm treatment. The whole blood was decreased and bone marrow suppression was found 4 cases of mild aplastic anemia. Therefore, during the application of radiotherapy and chemotherapy should be carefully used 153Sm, and closely monitor blood and bone marrow changes